Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipShort InterestTrends About ARCA biopharma Stock (NASDAQ:ABIO) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsWhy Trump’s Win Can’t Stop the Coming Crisis - Protect Yourself NowNo matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.Watch my emergency briefing here >>> Get ARCA biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.40▼$599.0452-Week Range N/AVolume290,800 shsAverage Volume607,995 shsMarket Capitalization$34.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More… Why Trump’s Win Can’t Stop the Coming Crisis - Protect Yourself Now (Ad)No matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.Watch my emergency briefing here >>> Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABIO Stock News Headlines18-Year-Old Sean Hingorani Makes It Back-to-Back ARCA West ChampionshipsNovember 9 at 9:38 AM | msn.comControversial ARCA Star Drops Heartbreaking Revelation as He Breaks Silence on Failing Career StabilityNovember 9 at 9:38 AM | msn.comWhy Trump’s Win Can’t Stop the Coming Crisis - Protect Yourself NowNo matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.November 12, 2024 | Behind the Markets (Ad)Bitget Expands GameFi Offerings with Legend of Arcadia (ARCA) Listing and Airdrop EventsNovember 5, 2024 | markets.businessinsider.comCall The Pizza Man: Brayton Laster Set To Run Full ARCA Season with Wayne Peterson MotorsportsNovember 1, 2024 | msn.comNASCAR Weekend at Rockingham Speedway to Include ARCA Menards Series EastOctober 11, 2024 | msn.comFMR LLC Acquires New Stake in ARCA biopharma IncOctober 8, 2024 | finance.yahoo.comNASCAR’s ARCA division releases 2025 schedule, will air Daytona opener on FOXSeptember 28, 2024 | msn.comSee More Headlines ABIO Stock Analysis - Frequently Asked Questions How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) issued its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) earnings per share for the quarter, topping the consensus estimate of ($341.28) by $292.32. When did ARCA biopharma's stock split? ARCA biopharma shares reverse split before market open on Tuesday, September 3rd 2024. The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Block (SQ), Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), Palantir Technologies (PLTR), ChargePoint (CHPT) and CrowdStrike (CRWD). Company Calendar Last Earnings8/04/2021Dividend Payable8/28/2024Ex-Dividend for 8/28 Dividend8/29/2024Today11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.18% Return on Assets-19.51% Debt Debt-to-Equity RatioN/A Current Ratio26.61 Quick Ratio26.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / BookN/AMiscellaneous Outstanding Shares14,507,000Free Float10,024,000Market Cap$34.82 million OptionableOptionable Beta0.91 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:ABIO) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWall Street’s “Secret” Land Grab33-year Wall Street veteran Dylan Jovine says there is one stock that could soar as high as 1,000% or more wit...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARCA biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABIO Stock Alerts